Stock GLUE MONTE ROSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Market Closed - Nasdaq
Other stock markets
 21:00:00 09/05/2024 BST 		5-day change 1st Jan Change
5.18 USD -1.52% Intraday chart for Monte Rosa Therapeutics, Inc. -7.50% -8.32%
05-09 Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-02 Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board CI

Evolution of the average Target Price on Monte Rosa Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

55473d90562d.i-OKW5MZ8QuIV65O8bnUuuvXBvNEdLj7PdyA9gTt--k.3K3FHtpyslHaYvs_ydui24OkVcUpJtSyWaXuuzHcyLbqhPgNwHefYvwU4w~308914a47fc4d081fa542b3cdafbc3eb

Analyst Recommendations on Monte Rosa Therapeutics, Inc.

UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating MT
Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target MT
Credit Suisse Trims Monte Rosa Therapeutics' Price Target to $11 From $12, Keeps Neutral Rating MT
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18 MT
UBS Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $22 Price Target MT
Jefferies Starts Monte Rosa Therapeutics at Buy With $20 Price Target MT
Piper Sandler Adjusts Price Target on Monte Rosa Therapeutics to $21 From $40, Reiterates Overweight Rating MT
Credit Suisse Initiates Monte Rosa Therapeutics at Neutral, $19 Price Target MT
Berenberg Bank Adjusts Monte Rosa Therapeutics' Price Target to $28 From $32, Maintains Buy Rating MT
Wells Fargo Starts Monte Rosa Therapeutics at Equalweight With $19 Price Target MT
Guggenheim Adjusts Price Target for Monte Rosa Therapeutics to $35 From $40, Maintains Buy Rating MT
Berenberg Bank Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $32 Price Target MT
MONTE ROSA THERAPEUTICS : SVB Leerink Starts Monte Rosa Therapeutics at Market Perform with $20 Price Target MT
MONTE ROSA THERAPEUTICS : JPMorgan Initiates Monte Rosa Therapeutics at Overweight Rating With $38 Price Target MT
MONTE ROSA THERAPEUTICS : Cowen Initiates Coverage on Monte Rosa Therapeutics With Outperform Rating MT
MONTE ROSA THERAPEUTICS : Piper Sandler Starts Monte Rosa Therapeutics at Overweight With $40 Price Target MT
MONTE ROSA THERAPEUTICS : Guggenheim Starts Monte Rosa Therapeutics at Buy With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.18 USD
Average target price
15.43 USD
Spread / Average Target
+197.85%
High Price Target
20 USD
Spread / Highest target
+286.10%
Low Price Target
9 USD
Spread / Lowest Target
+73.75%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Monte Rosa Therapeutics, Inc.

UBS
Wedbush
Credit Suisse
Wells Fargo Securities
Jefferies & Co.
Piper Sandler
Berenberg Bank
Guggenheim
SVB Leerink
Cowen
JPMorgan Chase

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GLUE Stock
  4. Consensus Monte Rosa Therapeutics, Inc.